An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications.

Aldose reductase, which catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds, is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney. A 1.65 angstrom refined structure of a recombinant human placenta aldose reductase reveals that the enzyme contains a parallel beta 8/alpha 8-barrel motif and establishes a new motif for NADP-binding oxidoreductases. The substrate-binding site is located in a large, deep elliptical pocket at the COOH-terminal end of the beta barrel with a bound NADPH in an extended conformation. The highly hydrophobic nature of the active site pocket greatly favors aromatic and apolar substrates over highly polar monosaccharides. The structure should allow for the rational design of specific inhibitors that might provide molecular understanding of the catalytic mechanism, as well as possible therapeutic agents.

[1]  D. Ewing,et al.  Six-Month Treatment with Sorbinil in Asymptomatic Diabetic Neuropathy: Failure to Improve Abnormal Nerve Function , 1987, Diabetes.

[2]  J. Kuriyan,et al.  Convergent evolution of similar function in two structurally divergent enzymes , 1991, Nature.

[3]  M Karplus,et al.  Anatomy of a conformational change: hinged "lid" motion of the triosephosphate isomerase loop. , 1990, Science.

[4]  Gregory A. Petsko,et al.  The evolution of a/ barrel enzymes , 1990 .

[5]  M. M. O'brien,et al.  Inhibition of Human Brain Aldose Reductase and Hexonate Dehydrogenase by Alrestatin and Sorbinil , 1982, Journal of neurochemistry.

[6]  S. Mckercher,et al.  Kinetic and structural effects of activation of bovine kidney aldose reductase. , 1989, Biochemistry.

[7]  C. Brändén,et al.  The TIM barrel—the most frequently occurring folding motif in proteins , 1991 .

[8]  R. Lazarus,et al.  What Makes a Good Computer Device? , 1985, Science.

[9]  C. Grimshaw,et al.  Mechanistic basis for nonlinear kinetics of aldehyde reduction catalyzed by aldose reductase. , 1990, Biochemistry.

[10]  B. Wermuth,et al.  Purification and characterization of human-brain aldose reductase. , 1982, European journal of biochemistry.

[11]  F A Quiocho,et al.  Atomic structure of adenosine deaminase complexed with a transition-state analog: understanding catalysis and immunodeficiency mutations. , 1991, Science.

[12]  Florante A. Quiocho,et al.  Stabilization of charges on isolated ionic groups sequestered in proteins by polarized peptide units , 1987, Nature.

[13]  S. Spielberg,et al.  In-vitro assessment of a hypersensitivity syndrome associated with sorbinil. , 1991, Annals of internal medicine.

[14]  N. Vyas.  Atomic features of protein-carbohydrate interactions , 1991 .

[15]  P. Kador.  The role of aldose reductase in the development of diabetic complications , 1988, Medicinal research reviews.

[16]  S. Sassa,et al.  Effects of metalloporphyrins on hemoglobin formation in mouse Friend virus-transformed erythroleukemia cells. Stimulation of heme biosynthesis by cobalt protoporphyrin. , 1982, The Journal of biological chemistry.

[17]  R. Poulsom.  Inhibition of hexonate dehydrogenase and aldose reductase from bovine retina by sorbinil, statil, M79175 and valproate. , 1986, Biochemical pharmacology.

[18]  S. Nakanishi,et al.  Structural similarity of bovine lung prostaglandin F synthase to lens epsilon-crystallin of the European common frog. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[19]  E. Pai.  Variations on a theme: the family of FAD-dependent NAD(P)H-(disulphide)-oxidoreductases , 1991 .

[20]  J. Kinoshita,et al.  The Pharmacology of Aldose Reductase Inhibitors , 1985 .

[21]  F. Quiocho,et al.  High specificity of a phosphate transport protein determined by hydrogen bonds , 1990, Nature.

[22]  B. Wermuth,et al.  The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. , 1989, The Journal of biological chemistry.

[23]  D. Dvornik,et al.  Polyol Accumulation in Galactosemic and Diabetic Rats: Control by an Aldose Reductase Inhibitor , 1973, Science.

[24]  P. Guzelian,et al.  Isolation and characterization of cloned cDNAs encoding human liver chlordecone reductase. , 1990, Biochemistry.

[25]  K. Bohren,et al.  Expression of human aldose and aldehyde reductases. Site-directed mutagenesis of a critical lysine 262. , 1991, The Journal of biological chemistry.

[26]  K. Skryabin,et al.  A novel type of crystallin in the frog eye lens , 1984, FEBS letters.

[27]  K. Gabbay.  The sorbitol pathway and the complications of diabetes. , 1973, The New England journal of medicine.

[28]  F A Quiocho,et al.  Carbohydrate-binding proteins: tertiary structures and protein-sugar interactions. , 1986, Annual review of biochemistry.

[29]  F. Quiocho.  Protein-carbohydrate interactions: basic molecular features , 1989 .

[30]  B. Lee,et al.  The interpretation of protein structures: estimation of static accessibility. , 1971, Journal of molecular biology.

[31]  J. Priestle,et al.  RIBBON: a stereo cartoon drawing program for proteins , 1988 .

[32]  S. Srivastava,et al.  Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors. , 1990, Biochemical pharmacology.